Summit Therapeutics INC Form 4 insider transactions

Co-CEO Mahkam Zanganeh acquired 3.81 million shares of Summit Therapeutics common stock at $13.12 per share.

Co-CEO Robert W. Duggan increased his stake in Summit Therapeutics by purchasing 3.81 million shares at $13.12 per share.

Co-CEO Robert W. Duggan increased his stake in Summit Therapeutics through a purchase of 100,000 shares at $14.60 per share.

Co-CEO Mahkam Zanganeh acquired 100,000 shares of Summit Therapeutics common stock at $14.60 per share.

Summit Therapeutics COO and CFO Manmeet Singh Soni purchased 50,000 shares of common stock in open market transactions.

Summit Therapeutics Inc. granted 30,000 stock options to Chief Accounting Officer Bhaskar Anand with an exercise price of $18.83, vesting annually over four years.

Mahkam Zanganeh's spouse received 11,232 stock options in Summit Therapeutics Inc. in lieu of $98,400 in director retainer fees.

Summit Therapeutics Inc. granted stock options for 11,232 shares to Co-Chief Executive Officer Robert W. Duggan in lieu of $98,400 in retainer fees.

Summit Therapeutics director Robert F. Booth acquired stock options for 42,180 shares, including some in lieu of retainer fees, signaling continued commitment.

Summit Therapeutics director Yu Xia was granted 35,000 stock options with an exercise price of $17.52, vesting quarterly in 2026.

Summit Therapeutics director Jeff Huber was granted 44,885 stock options with an exercise price of $17.52, with a portion issued in lieu of retainer fees.

Summit Therapeutics Inc. director Mostafa Ronaghi was granted 35,000 stock options with an exercise price of $17.52, vesting quarterly through 2026.

Summit Therapeutics director Kenneth A. Clark received stock options for 52,796 shares, with a portion granted in lieu of $155,900 in retainer fees.

Summit Therapeutics director Alessandra Cesano was granted 38,219 stock options with an exercise price of $17.52, including options in lieu of retainer fees.

Summit Therapeutics Director Yu Xia acquired 533,617 shares of common stock for approximately $10 million in a private placement.

Summit Therapeutics' Chief Accounting Officer, Bhaskar Anand, acquired 26,680 shares of common stock for approximately $500,000 in a private placement.

Manmeet Singh Soni, COO and CFO of Summit Therapeutics, acquired 53,361 shares of common stock for $18.74 per share in a private placement.

Summit Therapeutics Co-CEO Robert W. Duggan acquired over 14 million shares of common stock in a private placement at $18.74 per share, signaling strong confidence.

Summit Therapeutics Co-CEO Mahkam Zanganeh acquired over 14 million shares of common stock through a private placement at $18.74 per share.

Summit Therapeutics Inc. granted its Chief Accounting Officer, Bhaskar Anand, 50,000 stock options with an exercise price of $19.23, vesting annually over four years.

Summit Therapeutics Co-Chief Executive Officer Mahkam Zanganeh reported significant purchases of common stock, increasing her beneficial ownership.

Summit Therapeutics Co-CEO Robert W. Duggan acquired over 338,000 shares of company common stock in open market purchases totaling approximately $6 million.

Mahkam Zanganeh, Co-Chief Executive Officer of Summit Therapeutics Inc., reported that her spouse exercised options to acquire 74,545 shares of common stock, with the shares retained.

Summit Therapeutics Inc.'s Co-Chief Executive Officer and 10% owner, Robert W. Duggan, exercised options to acquire 74,545 shares of common stock at $2.64 per share and retained all shares, signaling continued confidence in the company.

Bhaskar Anand, Chief Accounting Officer of Summit Therapeutics Inc., received amended stock options that converted performance-based vesting to time-based vesting.

Manmeet Singh Soni, COO and CFO of Summit Therapeutics Inc., reports an amendment to stock options, changing them from performance-based to time-based.

Robert Duggan, Co-CEO of Summit Therapeutics, acquired stock options through an amendment converting performance-based options to time-based options.

Mahkam Zanganeh, Co-CEO of Summit Therapeutics, reports amended stock options converting performance-based options to time-based vesting.

Mahkam Zanganeh, Co-CEO of Summit Therapeutics, reports that her spouse exercised warrants to purchase 3,985,055 shares of the company's common stock at $1.58 per share.

Robert W. Duggan, Co-CEO of Summit Therapeutics, exercised warrants to purchase 3,985,055 shares of common stock at $1.58 per share.